Iconix Enters Chemogenomics Relationship with Taisho Pharmaceutical Co., Ltd.
DrugMatrix(R) to Support Taisho's Drug Discovery Activities
Under the agreement, Taisho will apply Iconix's DrugMatrix(R) platform, a large-scale chemogenomics reference database and informatics system, to enhance drug candidate selection and optimization. Taisho will also explore integrating Iconix's in vivo and in vitro chemogenomics technology into its current processes and key drug discovery efforts.
In addition, Iconix will use biomarkers of drug pathology and mechanism from its Drug Signature(TM) library, the largest collection of predictive biomarkers in the pharmaceutical industry, to profile select leads from Taisho's growing number of compounds. Drug Signatures are derived by Iconix from DrugMatrix.
"The use of chemogenomics supports increased productivity at pharmaceutical companies by allowing them to get better information, sooner," said Jim Neal, CEO of Iconix. "In working with Taisho, Iconix is leading the way to bring the power of genomics-based early toxicology profiling and technology to the Japanese pharmaceutical industry." Financial terms of the deal were not disclosed.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.